Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3985482
Max Phase: Preclinical
Molecular Formula: C18H15N5
Molecular Weight: 301.35
Molecule Type: Small molecule
Associated Items:
ID: ALA3985482
Max Phase: Preclinical
Molecular Formula: C18H15N5
Molecular Weight: 301.35
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc(/C=C/c2n[nH]c3ccc(-c4nnc[nH]4)cc23)cc1
Standard InChI: InChI=1S/C18H15N5/c1-12-2-4-13(5-3-12)6-8-16-15-10-14(18-19-11-20-23-18)7-9-17(15)22-21-16/h2-11H,1H3,(H,21,22)(H,19,20,23)/b8-6+
Standard InChI Key: ZJSHQKYVPYSBJO-SOFGYWHQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 301.35 | Molecular Weight (Monoisotopic): 301.1327 | AlogP: 3.83 | #Rotatable Bonds: 3 |
Polar Surface Area: 70.25 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.93 | CX Basic pKa: 2.57 | CX LogP: 3.33 | CX LogD: 3.33 |
Aromatic Rings: 4 | Heavy Atoms: 23 | QED Weighted: 0.60 | Np Likeness Score: -0.90 |
1. (2002) Indazole derivatives as JNK inhibitors and compositions and methods related thereto, |
Source(1):